Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

ior manager from big pharma, who has taken blockbuster drugs through development and into commercialization;
  • expansion of the Company's Board with experts in the biotech/pharma sector and in manufacturing; and
  • issuance of a dozen new patents in the Company's worldwide patent portfolio.
  • The Company's cash expenditures of $22.8 million for all of these operations in 2012 were substantially below the level of expenditures usually seen with companies that are in large Phase III clinical trials, and/or that have multiple product development programs under way, especially with operations on two continents.

    The Company's progress has continued to accelerate in 2013.  It differentiates NW Bio as a leader in immune therapies for cancer in multiple ways, including the following:

  • having 3 distinct product lines, with 2 products at the Phase III stage, and the 3rd product in the process of entering an unusually broad combined Phase I/II trial;
  • having 2 products that are each expected to be applicable to all solid tumor cancers (one for cases with tumors that are surgically removed and the other for inoperable tumors);
  • having manufacturing processes for 2 products that have been accepted by regulators for clinical trials at the Phase III level (which processes must be the same as will be used for commercialization) – a significant milestone, especially for cell therapy products;
  • having operations (both clinical and manufacturing) established in both the US and Europe, the 2 largest medical markets in the world;
  • having over 180 issued and pending patents worldwide;
  • having numerous chances to win in the near term, with 3 parallel product programs with ongoing value milestones;
  • having extensive external validations, through regulatory decisions from highly respected regulators in 3 countries (US, UK and Germany), and multiple large marquee partners. '/>"/>

  • SOURCE Northwest Biotherapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
    2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
    3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
    4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
    5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
    6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
    7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
    8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
    9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
    10. Palatin Technologies To Present At The 25th Annual ROTH Conference
    11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2015)... Philadelphia, PA (PRWEB) April 27, 2015 ... Phelix Therapeutics, the newest resident of the University ... Market Street in Philadelphia. , With a $4.5 ... of Health in hand, Phelix Therapeutics is ... is developing nutritional supplements. The company is developing first-in-class ...
    (Date:4/27/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) ... 2015 of $226.5 million, down 6%.  Excluding currency ... The Company reported a fourth quarter GAAP net ... Adjusted net income, exclusive of transformation, restructuring and ... up 1%, and adjusted earnings per share were ...
    (Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
    (Date:4/24/2015)... 24, 2015 The South Dakota School ... have entered into an agreement to promote cooperation on ... agreement signed by the universities will encourage and promote ... other services particularly, though not exclusively, relating to sustainability, ... strengths and a similar set of values,” said Michael ...
    Breaking Biology Technology:New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 31Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2
    ... - William Blair & Company 29th Annual Growth Stock Conference on ... Needham Life Sciences Conference on June 11 - , ... GPRO ) announced today that the Company will present at the ... at approximately 11:20 a.m. Central time (12:20 p.m. Eastern time) on ...
    ... Block The Attachment Of The Virus To The Nasal Membranes , ... Corporation (Pink Sheets: MNCN), an innovative, global wellness solutions company, announces ... hand carried and used as needed to form a mechanical barrier ... , , Peter Nash, Ph.D. and Chief Science Officer of ...
    ... June 4 Haemonetics Corporation (NYSE: HAE ) ... of Massachusetts has made a ruling in the Company,s lawsuit ... jury issued a verdict in favor of Haemonetics, finding that ... patent. The jury awarded Haemonetics $15.7 million in damages ...
    Cached Biology Technology:Gen-Probe to Webcast Two Upcoming Investor Presentations 2Mach One Corporation Developing a Nasal, Hand Carried Product as Solution to Swine Flu (H1N1) Virus 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
    (Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
    (Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
    (Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
    Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
    ... you,ve owned a pet guppy, you know they often jump out ... jumped; many a parent has been stumped for an answer. ... how guppies are able to jump so far, and suggests why ... that controls animal behavior, decided to study jumping guppies while researching ...
    ... Electronics group have come up with a novel solution ... organic semiconductor industry today. Oana Jurchescu, an assistant professor ... high performance organic semiconductor ,spray paint, that can be ... This is a potentially game changing technology for a ...
    ... reduced mortality in a mouse model of the neurodegenerative ... according to a new study by researchers at the ... published online ahead of print in the journal ... for melatonin are found in the nerve cells, a ...
    Cached Biology News:Why do guppies jump? 2High performance semiconductor spray paint could be a game changer for organic electronics 2Pitt team finds melatonin delays ALS symptom onset and death in mice 2
    Applications: ISH...
    ... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
    ...
    TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
    Biology Products: